Pulse
A focused laser pulse hits a cartridge holding a thin film of bio-ink.
The NGB platform is modular: laser and bioextrusion print living cells, hydrogels, and cell spheroids with high precision. Laser-Assisted Bioprinting, patented and validated on 40+ cell types, sets the benchmark for reproducibility, precision, and viability.
Create complex cell patterns with Laser-Assisted Bioprinting. It is based on laser-induced forward transfer: no nozzle, no mechanical contact with the cells.
A focused laser pulse hits a cartridge holding a thin film of bio-ink.
The pulse forms a jet that releases a picoliter droplet toward the substrate.
Rapid cartridge scanning deposits up to 10,000 droplets per second, with no shear stress.
A guided, reproducible workflow - the same result on every run, in any pair of hands.
Tune resolution through cell concentration and laser energy for ultra-precise 3D cellular constructs.
Print diverse bio-inks, cell types, and materials, with the exclusive ability to print cell aggregates.
The nozzle-free approach preserves cells, with viability up to 95%.
Alternatives can look cheaper to buy. For accuracy, viability, and the cost of use at scale, laser changes the equation.
The NGB platform combines laser and bioextrusion, so you are not forced to choose.

A completely robotized and automated laser bioprinting system, with a microfluidic cartridge, peristaltic pumps, and a 6-axis robotic arm enabling multicolor printing of up to three different cell types.
Combined with bioextrusion in the NGB platform, it covers research and clinical applications in one patented system.
See the NGB-R® system →Faithfully reproduce the 3D architecture, biochemical gradients, and multicellular interactions that govern tissue function in vivo, across oncology, drug testing, and regenerative medicine.
Structured TME models integrating tumour, stroma, immune compartments, and ECM mechanics. A more realistic test bed for immuno-oncology agents, biologics, and drug-resistance studies than conventional multicellular spheroids.
Autologous full-thickness skin substitute, 40 cm2, manufactured on NGB-C® under GMP-compatible conditions. Phase I/IIa trial (BIOPSKIN) in progress at AP-HM, Marseille.


Clinical-grade, GMP-compliant, for therapeutic applications and regenerative medicine.
Discover NGB-C® →Book a demo with our scientists, or download the full platform brochure.